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| INTRODUCTION
Breast cancer remains to be a major cause of cancer death in females worldwide. 1 Like several epithelial cancers, breast cancer is also a heterogeneous disease characterized by multiple pathological subtypes. 2 Despite the great development in medical science of breast cancer, the morbidity and mortality of breast cancer are still very high at present. 3 Early diagnosis and intervention treatment are essential for scientific research and clinical outcome of breast cancer. Furthermore, mounting evidence suggested that tumor biomarkers are of great clinical significance in tumor screening, diagnosis, and estimation of prognosis and treatment efficacy. 4 Thus, identification of tumor biomarkers for early diagnosis and clinical prognosis has been a hot topic of research.
Long non-coding RNAs (lncRNAs), a newly discovered class of ncRNAs with longer than 200 nucleotides in length, are widely involved in physiological and pathological processes of multiple malignancies by acting as enhancers, 5 scaffolds, 6 decoys, 7 and guides 8 in genome regulation. As previously reported, many lncRNAs are generally deregulated during carcinogenesis and tumor metastasis in a variety of tumors. 
| MATERIALS AND METHODS

| Study subjects
| Total RNA extraction and cDNA synthesis
Total RNA was extracted from tumor tissues using the TRIzol reagent (Invitrogen, CA, USA) following the manufacturer protocol and stored immediately at −80°C. The RNA purity were further detected with its OD 260/280 ranged from 1.8 to 2.0 to perform the subsequent experiments, and the cDNA was synthetized from 1 μg RNA template in a volume of 20 μL using PrimeScript RT reagent Kit with gDNA Eraser (Takara, Dalian, China).
| Quantitative real-time PCR
The Z38 expression was measured using SYBR Premix Ex TagTM 
| Statistical analysis
A paired Wilcoxon signed-rank test was employed to evaluate Z38 expression in breast cancer tissues versus adjacent normal tissues.
Correlations between Z38 expression and clinical features were per- 
| RESULTS
| Upregulation of Z38 in breast cancer specimens
To investigate expression of Z38 in tumor tissues, we used a QRT-PCR to detect the expression levels of Z38 from 110 breast cancer and corresponding normal breast tissue samples. The results showed that Z38 was highly expressed in breast cancer as compared with corresponding normal breast tissues (P<.001, Figure 1 Figure 2 ).
To further explore the association of Z38 expression with clinical characteristics, breast cancer patients were categorized as high or low expression group according to the optimal cut-off value of fold expression of Z38.
| Association between lncRNA Z38 expression and clinical characteristics in breast cancer
To identify the clinical relevance of Z38 expression in breast cancer, the association between Z38 expression and baseline characteristics was analyzed in 110 breast cancer tissues. The association of Z38 expression with baseline characteristics was summarized in T A B L E 1 Association between lncRNA Z38 and baseline characteristics F I G U R E 1 Relative levels of Z38 in breast cancer tissues samples. quantitative real-time PCR analyses to determine the relative levels of Z38 in a total of 110 breast cancer patients, a paired Wilcoxon signed-rank test was performed, *** indicate P <.001.
(P>.05). Collectively, these results suggest that high Z38 expression was associated with the development and progression of breast cancer.
| Prognostic value of Z38 in breast cancer
In 110 patients with breast cancer, the median follow-up time was 51 months. Fifty cases (45.5%) died (39 patients died of breast cancer, eight patients died of other malignancies, and three patients died of other diseases). At the cut-off value of Z38 expression, the 5-year overall survival (OS) rates of the high expression group versus the low expression group were 20.8% and 68.4% respectively (P<.001; ure 3 and Table 2 ). Significant factors in univariate analyses (Z38 expression, tumor grade, TNM stage, and lymph node metastasis) were further included in a multivariate Cox regression analysis. As shown in Table 3 , Z38 expression was an independent prognostic factor of OS in breast cancer patients (Hazard ratio=4.74, 95% CI=2.41-9.32, P<.001; Table 3 ).
| A nomogram for predicting overall survival
To accurately predict overall survival of breast cancer patients, a predictive model was constructed using the significant factors identified in univariate analyses (Table 3) . This model was performed through summing the points projected on the top scale for Z38 expression, 
| DISCUSSION
It is widely accepted that lncRNAs play a critical role of cancer origination and progression. Emerging studies started to focus on the regulatory roles of lncRNAs in cancer. For example, UCA1 acted as an endogenous sponge through recruiting miR-216b to upregulate fibroblast growth factor receptor 1 expression and activate ERK signaling pathway. 23 The small nucleolar RNA host gene 20 acted as a lncRNA to regulate cell proliferation, invasion and migration, and cell cycle progression in colorectal cancer cells. 24 Similarly, lncRNA Z38 could contribute to cell proliferation and tumorigenesis in breast cancer. 22 However, clinical relevance of lncRNA Z38 in breast cancer remains unknown. In the present study, our results indicated that Z38 expression was increased in breast cancer tissues compared with corresponding normal breast tissues. These data combined with a previous study showed that Z38
was overexpressed in breast cancer tissues and promoted cell proliferation and tumorigenesis of breast cancer cells. 22 We firstly explored the clinical implication of Z38 expression in breast cancer patients, providing a novel perspective on prognostic predication of breast cancer.
Furthermore, the constructed nomogram could conduct to predict clinical outcomes in breast cancer patients by its c-index and the calibration curve ( Figure 5 ). These findings reveal that Z38 may play an important role in the progression and prognosis of breast cancer, and it may be considered as a potential prognostic biomarker for breast cancer.
As we all know, breast cancer is a heterogeneous disease at the clinical characteristics and molecular levels. Traditional clinical factors, F I G U R E 3 Survival analysis in breast cancer patients based on Z38 expression. Overall survival based on high Z38 expression versus low Z38 expression in patients with breast cancer.
F I G U R E 2
Optimal cutoff value of Z38 expression determined by receiver operating characteristic curve for overall survival.
including TNM stage, tumor differentiation, lymph node status, seem not to be sufficient for predicting overall survival of breast cancer patients. With the development of epigenetics, lncRNAs, a recently found class of ncRNAs, have been involved in the tumorigenesis and development of cancer. 25 Although a series of lncRNAs have been correlated with cancer progression, the expression profile and prognostic significance of lncRNAs in breast cancer have not been systematically explored due to the lack of available samples and prognostic information of breast cancer. The lncRNA Z38 has been identified to promote cell proliferation and tumor growth through a series of in vitro and in vivo experiments. 22 In this study, lncRNA Z38 expression was significantly correlated with TNM stage and lymph node metastasis, but not correlated with ER status. However, previous investigations reported that several lncRNAs were associated with ER-positive tumors in breast cancer. For example, lncRNA BC200 expression is obviously lower in ER-negative tumors than in ER-positive tumors. 21 Concurrently, MALAT1 was also overexpressed in ER-positive breast cancer specimens. 26 The contradictory results indicate the spatial This study has several limitations: (1) The expression of lncRNA Z38 was only analyzed in tissues, and we will collect serum samples of breast cancer to further confirm our findings. (2) This study lacked of an independent cohort to identify the predictive value of this lncRNA signature. Thus, the findings of this study should be further confirmed for a larger sample in a multicenter, randomized, controlled, and prospective study.
In summary, we have shown a distinct expression pattern of lncRNA Z38 in breast cancer tissues compared with corresponding normal breast tissues. The lncRNA Z38 overexpression is markedly associated with shorter OS in patients with breast cancer. Therefore, Z38 is a potential biomarker in breast cancer patients. In the future, following studies will be essential to explore the molecular mechanism of Z38 in breast cancer.
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F I G U R E 4
Nomogram conveyed significant clinical characteristics and Z38 expression to predict overall survival of breast cancer patients.
Nomogram is interpreted by summing up the points assigned to each factor, which is indicated at the top of scale. The total points can be converted to predicted 3-y and 5-y probability of death for a patient in the lowest scale. The Harrell's c-indexes for overall survival prediction were 0.792. TNM, tumor-node-metastasis.
F I G U R E 5 Calibration curve for 5-y overall survival. The x-axis is its predicted probability of 5-y survival and y-axis is actual survival. The dashed line is 45 degree and presents perfect calibration.
